Hospital Stocks and Companies in India

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

• Rainbow Childrens Medicare Ltd
  What is helping: Premium pediatric/perinatal ARPOB durably parked at 32% (held through an 80% capacity addition, proven), zero debt + Rs 594cr cash self-funding the entire 900-bed pipeline, national niche leadership (20,000+ deliveries, no close competitor), IVF +25%/yr and a capital-light Indore O&M model.
  What could hurt: Growth guidance has been MISSED three times running ('late-teens/20%' -> 12% delivered); organic growth is only ~10% with 7-8% from acquisitions; pediatric seasonality + international geopolitical exposure are idiosyncratic; a new CEO is mid-transition. The clean '24% compounder' framing was flattering, durable organic base is more like 10% + seasonal swing.
• Global Health Ltd
  What is helping: Developing cluster ex-Noida is already at 31.5% margin growing EBITDA 35%; Lucknow/Patna are bed-CONSTRAINED at 68-70% occupancy (OTs being added H1 FY27 = a visible volume lever), the mature portfolio recovered to 26.7%, and Noida's sequential loss is narrowing (−320m -> −236m) toward H2-FY27 break-even as empanelments activate. Net-cash balance sheet funds it all;
• Fortis Healthcare Ltd
  What is helping: Diagnostics (Agilus +440bps margin) + brownfield bed absorption + maturation of loss-making acquisitions drive a credible 25%-hospital-EBITDA-by-FY28 path (1.5-2%/yr steps); the IHH parent's intended ->50% stake via ~Rs 10,000cr fresh equity de-risks the balance sheet (already low 1.24x) and funds the next M&A wave.
  What could hurt: Shalimar Bagh expansion slipped to FY29.
• Narayana Hrudayalaya Ltd
  What could hurt: Capital-allocation wanderlust, UK NHS (10% margin) and a loss-making Cayman insurance book ($5M/qtr at 110-112% combined ratio) keep dragging the blend; management has serially mis-guided every new-venture timeline (Cayman break-even retracted 3x, UK flipped EPS-accretive->dilutive in a quarter), so the offshore drag could persist longer than the mean-reversion thesis assumes.
• Park Medi World Ltd
  What is helping: Best fundamental profile of the IPO cohort: ~30% rev / ~48% PAT growth, best net margins (NPM 13-19%), ROCE ~19-20%, debt-free by Feb-2026, highest promoter alignment (83%); the Rs 700cr/2,010-bed plan is funded at Rs 34-35 lakh/bed (3x below peers) from internal cash, and a federally-mandated CGHS 12-15% rate hike lands on 83% of revenue from H2 FY27 (not yet in numbers).
• Jupiter Life Line Hospitals Ltd
  What could hurt: A quality name that can be dead-money for 2-3 years.
• Nephrocare Health Services Ltd
  What is helping: Asset-light dialysis network compounding ~30%+ on volume (+17.7%) + price (+12%) with 95% partner-contract stickiness and international scaling to 41% of mix; the Sep-2025 loss was a one-off non-cash CCPS-conversion finance charge (adjusted Q3 PAT +71%, 24.3% adjusted EBITDA at guide); net-cash post-IPO, ROCE jumped to 24.7%, structurally under-penetrated annuity market (only ~3 of ~42 lakh ESRD patients dialyzed).
• Dr Agarwals Health Care Ltd
  What is helping: High-GPM (~90%) asset-light day-care eye roll-up compounding revenue ~20%+ at steady 27% OPM; if the acquisition pace moderates (FY26 ICF already eased to −308), acquired clinics mature, NPM/ROE expand as goodwill amortization runs off, and the 90%-GPM annuity converts to real FCF.
• Max Healthcare Institute Ltd
  What is helping: ancillary engines (Max@Home +30%, digital Rs 838cr = 31% of revenue) and a Rs 140cr net CGHS tariff benefit from April-2026 offset the oncology clip; toward 8,000-8,500 beds by 2028.
• Healthcare Global Enterprises Ltd
  What is helping: EBITDA margin +70bps to 18.5% (mature centers 28-30% ROCE), Milann fertility divested, low-margin business pruned, a genuine, executing profitable-growth pivot toward a 20% group ROCE in 4-5 years.
  What could hurt: 12 years of ROCE 1-9% (never earned cost of capital) demands the PAT conversion be PROVEN not promised;
• Kovai Medical Center & Hospital Ltd
  What could hurt: Single-cluster (Coimbatore) concentration is a structural ceiling; growth capped at ~15%;
• Aster DM Quality Care Ltd
  What is helping: The India business is genuinely inflecting, normalised PAT +22%, mature (>7yr) hospital ROCE 36.2% (best in basket), MVT +41%, oncology mix to 11%; the QCIL/CARE merger (Q1 FY27) creates a 10,620+-bed network with 10-15% EBITDA synergy upside, turning a small carve-out into a scale-consolidation play.
  What could hurt: FIIs collapsed 38.6->17.2%. The entire forward thesis now rests on unproven QCIL integration.
• Yatharth Hospital & Trauma Care Services Ltd
  What is helping: Fastest grower (+46% YoY, 33pp same-store with Noida flagship at 91% occupancy), mature-hospital ADJUSTED EBITDA margin intact at 29.2% ex new-unit ramp losses, oncology mix climbing 10->15%, and management is deliberately cutting government-payer share to fix both AR and margin; if new Delhi-NCR beds cross 50% occupancy, the bought capacity converts to operating-leverage cash flow.
• Krishna Institute of Medical Sciences Ltd
  What is helping: Management has dated the recovery: Nashik broke even at month 13, Thane + Mahadevapura guided EBITDA-neutral by Q1 FY27, Electronic City Q3 FY27; debt has 'PEAKED' (FY27 capex drops to Rs 500-600cr, no incremental debt); group ARPOB +20.5% to Rs 70,000+ on the value->premium-metro mix-up; demand-constrained (losing patients to bed shortage).

• Apollo Hospitals Enterprise Ltd
  • Mature-asset occupancy operating leverage: established hospitals run 26.5% EBITDA at only 69% occupancy, with 7-8% utilization headroom worth Rs 100-125cr incremental EBITDA before the new beds even ramp (2026-05) source
  • Fresh 1,500-bed metro cohort (~25% capacity) layering a new J-curve on a 25.4%-ROCE base; Rs 140cr FY27 startup drag (peaks Q2), cluster breakeven FY28, a bounded, proven-operator J-curve (2026-05) source
• Max Healthcare Institute Ltd
  • Capital-light non-bed engines: Max@Home Rs 73cr (+30%, 56% repeat) + Max Lab + digital Rs 838cr (31% of network revenue), accretive layers diversifying away from the all-NCR-beds concentration (2026-05) source
  • NEGATIVE lever: CGHS Oct-2025 30%-MRP rule permanently clipped the high-margin oncology mix 26->21% (Rs 200cr gross / Rs 140cr net), a structural re-set of the best engine, partly offset by a Rs 140cr CGHS tariff benefit from Apr-2026 (2026-05) source
• Fortis Healthcare Ltd
  • Operating leverage off a cleaned base: hospital EBITDA margin 20->21.7%, FY26 EBITDA +31% on +19% revenue, with an explicit 25%-by-FY28 path in 1.5-2% annual steps (2026-05) source
  • IHH parent ->50% stake via ~Rs 10,000cr fresh equity de-risks the 1.24x-levered sheet and funds the next M&A wave, parent conviction in its 'India growth engine' (2026-05) source
  • Agilus diagnostics second engine: margin +440bps to 23.6% on operating leverage + specialized/preventive mix, offset by the live Gleneagles acquisition underperformance (−4% 9M, clinician attrition) (2026-02) source
• Narayana Hrudayalaya Ltd
  • Efficiency-led throughput model: India hospital margin EXPANDED 360bps to 25.1% with ZERO net beds added since listing, case-mix/payer optimization rivals new-bed growth without the FCF/leverage cost (2026-05) source
  • Mean-reversion lever: the consolidated drag is offshore (UK NHS ~10% margin + Cayman insurance bleed at 110-112% combined ratio); as UK private-pay rises from 7% and Cayman pricing repairs (30-35% hikes), the blend converges back toward the 25% India core (2026-05) source
  • Quaternary-care moat + oncology emergence: Bangalore robotic cardiac / BMT differentiation, oncology now the 2nd-largest specialty; Rajarhat Calcutta greenfield to lift East ARPOB toward the Bangalore template (2026-02) source
• Global Health Ltd
  • Portfolio-decomposed margin: mature 26.7% + developing ex-Noida 31.5% (35% EBITDA growth), the OPM dip is ONE asset (Noida at 30% occupancy, loss narrowing −320->-236m), not broad J-curve dilution (2026-05) source
  • Bed-CONSTRAINED not demand-constrained: Lucknow 68% / Patna 70% occupancy growing 30%, OTs being added H1 FY27 = a visible falsifiable volume lever on a 31%+ margin engine (2026-05) source
  • Self-funded build: exits FY26 NET CASH Rs 5,906m with OCF Rs 7,144m (21% CAGR), DE 0.25, the negative FCF is a chosen capacity build behind a fortress balance sheet (2026-05) source
• Aster DM Quality Care Ltd
  • Scale-consolidation: QCIL/CARE merger (Q1 FY27) creates a 10,620+-bed network with 10-15% near-term EBITDA synergy, value now hinges on integration, not the one-off FY25 gain (2026-02) source
  • Mature-asset economics: ex-new-Kasargod margin +90bps to 20.2%, mature (>7yr) hospital ROCE 36.2%, the highest mature-asset return discipline in the basket, funding the Rs 2,000cr/1,700-bed expansion (2026-02) source
• Krishna Institute of Medical Sciences Ltd
  • Dated J-curve recovery: Nashik breakeven at month 13, Thane + Mahadevapura by Q1 FY27, Electronic City Q3 FY27, fixed costs sunk, 'the losses only should come down' as revenue ramps (2026-02) source
  • Debt 'PEAKED': FY27 capex drops to Rs 500-600cr (project closure), no incremental debt, deleveraging path benefits PAT via lower interest, converts the open-ended leverage flag to a defined peak (2026-02) source
• Rainbow Childrens Medicare Ltd
  • Premium-ARPOB durability proven: 32% OPM held through an 80% capacity addition + two integrations (gross 86-87% vs 73-74% industry), the pediatric/perinatal niche commands and KEEPS its pricing (2026-05) source
  • ZERO debt + Rs 594cr cash self-funding the full 900-bed pipeline + capital-light Indore O&M + IVF +25%/yr, strongest balance sheet in the basket, national pediatric moat (2026-05) source
  • CAUTION lever: clean '24%' growth is flattered, organic only ~10% (7-8% acquired), seasonality cost 6-8pp, growth guidance missed 3x, new CEO mid-transition; size for 10-12% organic (2026-05) source
• Healthcare Global Enterprises Ltd
  • NEGATIVE/governance lever: rights issue contradicting prior 'internal-accruals only' guidance (dilution) + related-party Milann sale to the promoter's own fund + promoter destake 71->64%, amber capital-allocation flags that temper the pivot (2026-05) source
• Jupiter Life Line Hospitals Ltd
  • Mature Thane asset anchors a sticky 23% OPM but margin has STOPPED expanding (opm_delta 0), easy operating-leverage gains banked; further uplift needs the new Thane/Pune beds to mature (next J-curve cohort) (2026-03) source
  • FCF −174cr, EPS growth cooled to 11% (verify FY24 PAT spike was operating not one-off) (2026-03) source
• Yatharth Hospital & Trauma Care Services Ltd
  • Mature-asset core intact: adjusted EBITDA 29.2% ex new-unit ramp losses, Noida flagship at 91% occupancy, oncology mix 10->15%; deliberately cutting govt-payer share (35%) to fix AR AND margin (2026-02) source
• Artemis Medicare Services Ltd
  • Single Gurugram asset crossed occupancy break-even after ~8 sub-scale years; incremental patients drop to the bottom line at high contribution margin (the decade of flat 11% OPM was the durability answer), OPM now 17-18% EXPANDING (2026-03) source
  • FII spike 0.3->12.5% validates the turn arriving at the start (2026-03) source
• Park Medi World Ltd
  • Capital-efficient self-funded rollout: Rs 700cr/2,010-bed plan at Rs 34-35 lakh/bed (3x below peers) funded from OCF + cash, gross term loan just Rs 28cr, caps the FCF drag the data feared (2026-05) source
  • Unbooked CGHS 12-15% rate-hike tailwind on 83% govt payer mix (mgmt models 5-6% net), first benefit Q2 FY27, NOT yet in numbers; the Q4 margin beat came from occupancy alone (2026-02) source
• Nephrocare Health Services Ltd
  • Asset-light per-session dialysis scaling: volume +17.7% + price +12%, 95% partner-contract stickiness, international 12->41% of mix lifting realisation; structurally under-penetrated annuity market (2026-02) source
• Dr Agarwals Health Care Ltd
  • Asset-light day-care eye roll-up: ~90% GPM but ~20pp OPM-to-NPM gap consumed by acquisition D&A + interest; (2026-03) source

• Apollo Hospitals Enterprise 2026-05: Confirms the OPM 10->15% climb is mature-asset operating leverage, not mix-masking. Existing hospitals already run 26.5% EBITDA at only 69% occupancy; the consolidated 15% is dragged down by lower-margin pharmacy/HealthCo. There is Rs 100-125cr incremental EBITDA still to come from occupancy + cost levers BEFORE the new beds even ramp. Apollo management (Q4 FY26 call)
• Apollo Hospitals Enterprise 2026-05: Strips the pharmacy-dilution question: ex new hospitals, established-hospital revenue compounds 13-14% organically (7% volume + 5% mix + 4% price), ARPP +9% from a shift to high-complexity cardiac/oncology/neuro (specialty +22%). Healthcare-services ROCE 25.4%, the hospital engine is real and capital-efficient; the J-curve is layered on a high-return base. Apollo management (Q4 FY26 call)
• Apollo Hospitals Enterprise 2026-03: OCF tripled cleanly; FY25 investing −3381 is a deliberate debt-funded bed-addition wave (financing +1317), CWIP 1026cr live. FCF only 708 because capex is heavy, expansion capex, not WC bleed (debtor days flat 37-50). Highest gearing in group (D/E 0.88, borrowings 7987cr), backed by hospital fixed assets. screener_cash_flow table
• Apollo Hospitals Enterprise 2026-05: Goal Rs 25,000cr revenue at 6.5-7% EBITDA; digital cash losses already collapsed Rs 80cr -> Rs 16cr toward breakeven Q1 FY27. Apollo management (Q4 FY26 call)
• Apollo Hospitals Enterprise 2026-05: Said-vs-delivered MIXED-POSITIVE: beats are real and recurring (Q4 rev +16%, EBITDA +25%, PAT +34%) with ARPP/ROCE tracking, but Feb-2026 guided ~40-50% of the 1,500-bed pipeline live by Q1 and only 185 beds were operational by May, benchmark pushed to mid-FY27. High integrity, mild over-promising on timelines. Apollo management (Q4 FY26 call)
• Max Healthcare Institute 2026-03: The 27% OPM is structurally the highest of the group, built from the 2020 Radiant/Max merger into a clustered high-ARPOB Delhi-NCR network. Pre-merger Max ran 7-9% (even loss-making FY18); the step-change to 24-28% from FY22 is genuine business reconstitution, not cyclical froth. 8q band 25-29% = stable at the top, leaving little headroom above. screener_annual_results table
• Max Healthcare Institute 2026-05: The numbers called the 27% OPM 'peak-cycle that may mean-revert'. The concall shows the mechanism: a new Oct-2025 CGHS rule (30% MRP discount on medicines, first in 14 years) forced Max to discontinue high-value chemo, dropping oncology inpatient mix 26->21% (Rs 200cr gross / Rs 140cr net hole). Management says oncology will NOT recover to 25-26%, a permanent re-set of the high-margin engine the numbers couldn't see. Max management (Q4 FY26 call)
• Max Healthcare Institute 2026-05: The numbers flagged FCF −56 as a J-curve. The concall quantifies scale: a Rs 1,400cr board-approved 700-bed Lucknow greenfield PLUS a 570-bed Gomti Nagar brownfield, on top of a 500-bed Gurgaon greenfield and a 20%+ network brownfield rollout. FY26 capex Rs 1,900cr, net debt guided +Rs 500-600cr but kept <1x net-debt/EBITDA. A debt-disciplined empire-build, larger and longer than the snapshot implies (toward 8,000-8,500 beds by 2028). Abhay Soi (Q4 FY26 call)
• Max Healthcare Institute 2026-03: Quality is real but priced beyond it. computed_fair_values table
• Max Healthcare Institute 2026-05: The concalls show a consistent slippage pattern: Gurgaon greenfield slipped end-CY25 -> end-FY26 -> end-H1-FY27 -> end-FY27 across four calls; Lucknow bed goal missed (550->426 actual, deferred 2q); brownfield first called 'immediately accretive' then blamed for margin contraction. A credibility-on-guidance flag, not governance fraud (Dwarka's 6-month break-even is the offset). Max management (Q4 FY26 call)
• Fortis Healthcare 2026-03: The single biggest margin repair in the group. FY14-19 OPM 2-8% reflected Singh-brothers-era mismanagement + over-leverage; post-IHH control the business was cleaned. The climb 13%(FY20)->23%(FY26) is structural cost discipline + diagnostics (Agilus) mix + occupancy recovery. Op profit 231cr(FY19)->2085cr(FY26) = 9x on 2x revenue = real operating leverage off a broken base. screener_annual_results table
• Fortis Healthcare 2026-05: Confirms the repair is structural operating leverage, not a one-off, EBITDA growing 31% on 19% revenue is textbook leverage; >20%-margin facilities rose 10->13 of 47. Management gave an explicit FY27 path: +150bps and a 25% hospital EBITDA goal by FY28 in 1.5-2% annual steps, driven by brownfield absorption + maturation of loss-making acquisitions. Dr. Ashutosh Raghuvanshi, CEO (Q4 FY26 call)
• Fortis Healthcare 2026-05: IHH (parent) intends to lift its stake to 50% with a ~Rs 10,000cr fresh equity infusion, capital for debt paydown (net debt/EBITDA only 1.24x) and the next acquisition wave. Signals parent conviction (IHH calls Fortis its 'India growth engine') and funds the brownfield/M&A pipeline without straining the sheet. Fortis CFO (Q4 FY26 / Q3 FY26 calls)
• Fortis Healthcare 2026-02: Clears the Stage-A 'WC/leverage creep' worry: the Q3 PAT decline was entirely a non-recurring Rs 55cr New Labour Code provision, PBT before exceptional grew 21.9%, so the cash engine is intact (OCF −179->1601). FY27 capex Rs 900cr (60% maintenance / 40% growth), 1,800-bed pipeline funded from a 1.24x sheet + the IHH infusion. Fortis management (Q3 FY26 call)
• Fortis Healthcare 2026-02: Two divergent sub-stories. Agilus (diagnostics) inflected hard, +440bps margin on operating leverage + specialized/preventive mix, a second high-margin engine. BUT Gleneagles is the live underperformance: 9M revenue −4% on clinician attrition + management churn, turnaround promised FY27. Candid disclosure is a governance positive; it is also the key execution risk to the durability case. Fortis management (Q3 FY26 call)
• Narayana Hrudayalaya 2026-05: The numbers inferred an inorganic Indian hospital acquisition (Health City Cayman) diluting margins. The concall corrects this: the revenue step is (a) the UK Practice Plus Group (closed Sep-2024, £150m, ~93% NHS-contracted, 5 months consolidated) and (b) Cayman insurance scaling. NH's INDIA hospital business added ZERO net beds since listing, a pure efficiency operator. The consolidated dilution is NOT a domestic bed J-curve at all. NH management (Q4 FY26 call)
• Narayana Hrudayalaya 2026-05: The biggest miss in the numbers-only read, which concluded the core engine was 'diluted, OPM falling'. The concall shows the OPPOSITE for the India business: Q4 India hospital EBITDA margin EXPANDED 360bps to 25.1% (from 21.5%) on Bangalore quaternary case-mix (robotic cardiac, BMT) + payer-mix optimization. The legacy high-ROCE engine is intact and improving; the consolidated drag is entirely UK (~10% margin) + Cayman insurance bleeding ~$5M/quarter at a 110-112% combined ratio. NH management (Q4 FY26 call)
• Narayana Hrudayalaya 2026-05: The numbers read FCF −2079 / rising debt as a debt-funded acquisition. The concall attributes it to the £150m UK acquisition debt + a fresh Rs 3,000cr FY27-28 India greenfield reset (~Rs 1,000cr/yr for Rajarhat Calcutta, HSR Bangalore, Raipur, Central Bangalore). Net debt/EBITDA held <2.5x, forward growth capex + an offshore acquisition with a discipline ceiling, not distress. NH management (Q4 FY26 call)
• Narayana Hrudayalaya 2026-05: A material qual flag: management has serially retracted new-venture guidance. Cayman insurance break-even pushed 'end-of-year' -> 'too early to say' -> 'challenging to predict'; UK flipped from 'EPS neutral to mildly positive' to openly 'consolidated PAT and ROE diluted'; India clinic+insurance losses called 'declining' for two calls then admitted FLAT at Rs 66cr; plus a full Northern-cluster strategy U-turn. The core India operating story is credible; the diversification adventures are repeatedly mis-guided. NH management (Q4 FY26 call)
• Narayana Hrudayalaya 2026-02: Two real forward catalysts: oncology is now NH's second-highest specialty with the fastest growth (cardiac+oncology projected >50% of revenue), and the Rajarhat Calcutta greenfield replicates Bangalore's quaternary capability (50+ BMT beds vs the current 10-bed constraint) to bridge the East-vs-Bangalore ARPOB gap. The investable thesis is mean-reversion as UK + Cayman repair toward the 25% India core. NH management (Q3 FY26 call)
• Global Health 2026-05: The numbers read OPM 25.2->19.4% as a generalized new-bed J-curve. The concall decomposes it cleanly: mature portfolio (Gurugram/Indore/Ranchi) Q4 margin RECOVERED to 26.7%; developing ex-Noida (Lucknow/Patna) at a stellar 31.5% (+140bps, 29% rev / 35% EBITDA growth); the entire consolidated drag is NOIDA alone (Rs 783m loss on Rs 966m revenue at 30% occupancy). The margin dip is one identifiable ramping asset, not broad dilution. Medanta management (Q4 FY26 call)
• Global Health 2026-05: The numbers flagged negative true-FCF on a Rs 1,300cr fixed-asset jump. The concall reframes: despite the heavy build, Medanta exits FY26 in a NET CASH position of Rs 5,906m with OCF Rs 7,144m (21% 4-yr CAGR), funding capex from internal accruals + project-specific debt (DE 0.25). The negative FCF is a chosen, self-funded capacity build with a fortress balance sheet behind it. Medanta management (Q4 FY26 call)
• Global Health 2026-03: The inflection is mature-asset leverage layered with a fresh capex cohort (Lucknow/Patna), supporting an early-innings read; ROCE rebuilt to high-teens, DE only 0.25. pe_pb_expansion_snapshots · MEDANTA
• Global Health 2026-05: A concrete catalyst: Lucknow (6.5yr) and Patna (4.5yr) grow ~30% YoY at 68%/70% occupancy, management says the constraint is PROCEDURAL CAPACITY (operating theatres), not demand. They are adding 4-5 OTs each in H1 FY27 + critical-care beds. So the 31%+ developing-cluster engine has a clear, falsifiable volume lever about to be pulled; Noida's sequential loss improvement points to H2-FY27 break-even as empanelments activate. Medanta management (Q4 FY26 call)
• Global Health 2026-05: The qual flag the numbers miss: capital-plan credibility wobbled. FY27 capex guided 'below Rs 500cr' (Feb) then jumped to Rs 800-900cr (May) with no bridge; the 5-yr plan expanded ~50% (Rs 3,000->4,500cr); a no-guidance policy was reversed within a quarter (then gave specific H2-FY27 Noida break-even); Noida 'peak loss' missed (Rs 197m -> 320m). Not governance fraud, but a pattern of optimistic-then-revised capital guidance. Medanta management (Q4 FY26 call)
• Global Health 2026-02: The numbers showed 19% rev CAGR but not the mix. Management consciously reset ARPOB growth to 5-7% (from post-Covid double-digit), with growth driven by IPD +16%, OPD +19%, complex-procedure scaling (robotics, transplants, oncology daycare) and ALOS improvement. Patna has had NO major tariff increases in 4 years, leaving latent pricing headroom. Durable, volume-led, low-price-risk growth, higher quality than a price-led print. Medanta management (Q3 FY26 call)
• Aster DM Quality Care 2026-03: Confirmed GCC demerger: the consolidated 10253cr (FY22) included the Gulf clinics/hospitals/pharmacies; the FY23 drop to 2994cr is the India-only carve-out. Aster India is now a ~4643cr-revenue India hospital operator (OPM ~19%) after divesting the larger GCC business, a completely different, much smaller company than the pre-FY23 numbers. screener_annual_results table
• Aster DM Quality Care 2026-03: FY25 net_profit 5408cr (EPS 107.66) is the GCC DIVESTITURE GAIN, not operating earnings, corroborated by FY25 financing −6358 and investing +6015. Strip it: real FY26 PAT 427cr (EPS 7.49). At price 813 that is ~108x trailing on clean earnings; FY25 is a non-recurring artifact. screener_annual_results + computed_fair_values
• Aster DM Quality Care 2026-02: Decomposes the margin: reported 18.9% is held back by the new Kasargod facility (J-curve); strip it and margins EXPANDED 90bps to 20.2%, core hospitals 21.4%. Crucially, mature (>7yr) hospitals deliver 14% rev / 17% EBITDA growth at a 36.2% ROCE, the highest mature-asset return discipline in the basket. Aster DM management (Q3 FY26 call)
• Aster DM Quality Care 2026-02: The India story is no longer a small carve-out, it is a scale-consolidation play. The post-divestiture entity is executing a transformational merger with QCIL (CARE Hospitals), completion Q1 FY27 (NCLT filed Dec-2025), creating one of India's largest networks (10,620+ beds) with 10-15% near-term EBITDA synergy from procurement/operational efficiencies. Value now hinges on merger execution, not the one-off FY25 gain. Aster DM management (Q3 FY26 call)
• Krishna Institute of Medical Sciences 2026-02: Directly answers 'does mgmt explain the new-unit drag?', YES, granularly. Management states the entire 550bps OPM compression + the −44% PAT come from EBITDA erosion of newer units commenced over the last 9-12 months. The gross line is stable (GPM 78-80%), so it is below-the-line new-unit opex + depreciation + interest, the textbook leveraged-expansion J-curve, not demand deterioration. The roll-up revenue engine is intact (+35% TTM). KIMS management (Q3 FY26 call)
• Krishna Institute of Medical Sciences 2026-02: The most important answer to the debt-funded land-grab flag (borrowings 257->4253cr, DE 1.4). Management says debt has PEAKED, most capex is complete, FY27 capex drops to Rs 500-600cr (project closure), no incremental debt expected, balance falling as accruals rise. Converts the leverage flag from open-ended to a defined peak with a deleveraging path that benefits PAT via lower interest. KIMS management (Q3 FY26 call)
• Rainbow Childrens Medicare 2026-05: The numbers' best call confirmed: OPM held at 32% (Q4 31.5%) DESPITE an 80% capacity addition + two integrations, proving the premium pediatric/perinatal ARPOB is genuinely durable (gross 86-87% vs industry 73-74%). The forward mechanism: blended occupancy is only 45.3% (goal 56-57%), so the FY27 '20% growth, margins maintained' commitment rests entirely on occupancy-driven operating leverage. The margin is the asset; occupancy recovery is the unproven near-term lever. Rainbow management (Q4 FY26 call)
• Rainbow Childrens Medicare 2026-05: The numbers-only read called Rainbow 'a clean ~24% inflection... monotonic'. The concall is more sobering: Q4 rev +24% but FULL-YEAR FY26 only +12%, of which organic (ex-acquisitions/new-units) is just ~10%, acquired units (Vizag/Guwahati) contribute 7-8%. Normalized seasonality would have yielded 18-20% (so 6-8pp was lost to weak seasonal illness + geopolitical disruption). The durable organic base is ~10% + seasonal swing, not 24%. Rainbow management (Q4 FY26 call)
• Rainbow Childrens Medicare 2026-05: The numbers called the WC + balance sheet 'cleanest combo'. The concall strengthens it: ZERO debt, Rs 594cr cash, the full 900+-bed 3-year pipeline (Gurgaon, Coimbatore, Pune, Malad) funded ENTIRELY from internal accruals, 75.8% cash-flow-to-EBITDA conversion, maintenance capex just Rs 40-45cr/yr. The only nuance: the all-cash stance 'caps M&A optionality', the trade-off being deliberately constrained inorganic firepower. Rainbow management (Q4 FY26 call)
• Rainbow Childrens Medicare 2026-01: Qual flags: (1) growth guidance serially missed ('~20%' -> '20% CAGR' -> 12% actual); (3) a NEW Group CEO (Abrar Dalal) took over Jan-2026 with founder Dr. Kancharla moving to Chairman; (4) Gurgaon capex ballooned Rs 150cr->400cr. High-quality asset, but a shakier guidance/execution track record than the clean numbers imply. The new CEO is a sensible response to the execution gap. Rainbow management (Q3 FY26 call)
• Rainbow Childrens Medicare 2026-05: The forward thesis: Rainbow is the LARGEST pediatric/perinatal provider nationally with no close competitor, a defensible single-specialty niche. ALOS 2.7 days is industry-leading. Niche dominance + zero debt + capital-light expansion is genuinely differentiated. Abbrar Dalal (Q4 FY26 call)
• Kovai Medical Center & Hospital 2026-03: OPM rock-steady 27-29% with no new-unit drag because expansion is incremental at the existing Coimbatore cluster (operating leverage already captured), mature-asset margin discipline. No J-curve because there is no fresh bed cohort to dilute. screener_annual_results table
• Kovai Medical Center & Hospital 2026-03: Best returns + WC in the batch: 22-23% ROCE, 5-9 day debtors (cash-pay/low-credit mix), falling debt, EPS 95->223 FY22-26, promoter 56% rising. screener_ratios + pe_pb_expansion_snapshots
• Healthcare Global Enterprises 2026-02: The concall addresses it: pre-tax ROCE is now 14%, MATURE centers clock 28-30% ROCE, and management guides the GROUP to 20% in 4-5 years as new centers cross Rs 10cr/month and capex slows post-FY27. Mechanism: operating leverage from existing-center optimization (75-80% of next-2-yr growth from existing hospitals) + payer-mix shift. HCG management (Q3 FY26 call)
• Healthcare Global Enterprises 2026-03: ROCE 1-9% for all 12 years, never earned its cost of capital. The fresh rights issue attacks this, but the conversion to owner-earnings must be PROVEN. screener_ratios + annual_results
• Healthcare Global Enterprises 2026-05: A concrete cleanup catalyst: HCG divested its 13-year-old Milann fertility business (declined 9->6 centers, marginally profitable) to Inviga Healthcare for Rs 37.6cr. This removes a persistent low-margin drag and concentrates capital on the high-ROCE oncology core. HCG management (Q4 FY26 call)
• Healthcare Global Enterprises 2026-02: Genuine governance flags that TEMPER the bull pivot: (1) Dec-25 management was 'very clear' greenfield would be internal-accruals-funded, then two months later announced the Rs 425cr rights issue despite 'comfortable' debt, diluting holders; (2) the Milann divestment was promised 'this fiscal year' (May-25) and kept slipping until May-26; Ajaikumar PROMOTER group, a related-party transaction; (4) promoter cut stake 71%->64% (Jun-25). The pivot is real but the capital-allocation hygiene is the open question. HCG management (Q3 FY26 call)
• Healthcare Global Enterprises 2026-05: The concall is explicit: Q4 revenue grew only 11.3% because management CONSCIOUSLY exited low-margin business AND faced medical-value-travel disruption from the Middle-East conflict, both being restored. Underlying demand is intact: 12% base volume growth, OPD +26%/IPD +37% (Q3), digital revenue +26% on REDUCED paid-media spend, aggregator dependence cut 12->9%. HCG management (Q4 FY26 call)
• Jupiter Life Line Hospitals 2026-03: Mature Thane asset anchors a sticky 23% margin, among the best in the batch, but margin has STOPPED expanding, signalling the easy mix/operating-leverage gains are banked; further uplift now needs the new Thane/Pune beds to mature (the next J-curve cohort). screener_annual_results table
• Yatharth Hospital & Trauma Care Services 2026-02: Directly explains the 28->23% OPM contraction: it is PURELY new-unit J-curve drag, not mature deterioration. Strip the new New-Delhi/Faridabad ramp losses and mature EBITDA margin is 29.2%, the historic level intact. The 23% blended print is the dilution of a fast-growing denominator; the inflection comes as new beds cross ~50% occupancy. Yatharth management (Q3 FY26 call)
• Yatharth Hospital & Trauma Care Services 2026-03: The key red flag: AR ballooned to 113-131 days (vs JLHL 18, INDRAMEDCO 28), a payor-mix/collection problem that turned FY24 OCF NEGATIVE. Cash conversion is structurally weak and the −598cr capex is debt+equity funded (financing +254-520cr), so growth is consuming, not generating, cash. Management is cutting govt-payer share (35%) and targeting 105-110 days by Mar-2027, bounded but unresolved. screener_ratios + cash_flow
• Yatharth Hospital & Trauma Care Services 2026-02: The most consistent guidance-miss record: Agra ARPOB guided >Rs 30,000 delivered Rs 26-27k (reframed 'quite good'); Delhi ARPOB guided Rs 38,000 delivered Rs 33,600 (−12%); new-hospital breakeven repeatedly pushed and self-contradicting; Rs 1,500cr capex timeline stretched 3yr->4.5-5yr; brownfield 'available in 15-18mo' but only 'basic construction started' by May-26. Mgmt beat the 30% revenue guidance (+46%) but forward promises are serially missed, trust the mature 29% margin, discount every forward claim. Yatharth management (Q4 FY26 call)
• Artemis Medicare Services 2026-03: The cleanest structural turnaround in the batch, a single large Gurugram asset that sat sub-scale for ~8 years finally crossed its occupancy break-even, and incremental patients drop to the bottom line at high contribution margin. The decade of flat 11% margin is the durability answer: this is operating leverage on a now-mature asset, not a one-off. screener_annual_results table
• Artemis Medicare Services 2026-03: AR well-controlled at ~40 days, so OCF cleanly funds the now-lighter capex and FCF turned positive (+42cr, only one in the batch alongside marginal INDRA). CWIP collapsed 95->28cr = harvest phase. The FY25 PAT jump (49->82cr) was real operating leverage (op_profit 133->152cr), and the FII spike 0.3->12.5% in one quarter is institutional validation of the turn arriving at the start, not the end. screener_cash_flow + shareholding
• Artemis Medicare Services 28 April 2026: Social peer-contrast: Artemis is flagged as already at mature occupancy (>60%) and rated Neutral by the voice, i.e. less incremental greenfield occupancy headroom than the ramping names. Shankar Nath
• Indraprastha Medical Corporation 2026-03: A fortress cash cow: 36-39% ROCE (vs 12-18% peers) on an asset needing almost no reinvestment, returning cash via dividends/debt-paydown every year (financing CF always negative). screener_ratios + cash_flow + computed_fair_values
• Indraprastha Medical Corporation 2026-03: 100% mature same-store, no new beds, no CWIP, no expansion for 10+ years. Revenue growth has decayed to single digits because a single fixed-bed hospital can only grow on ARPOB/case-mix once full. screener_growth_metrics + balance_sheet
• Park Medi World 2026-02: Quantifies a structural revenue tailwind the data can't see: a federally-mandated 12-15% rate hike lands on 83% of revenue with zero commercial effort. Management is deliberately conservative (models 5-6% net) and flags it is NOT yet in reported numbers, the Q4 margin beat came from occupancy, not the hike, so this is incremental upside to FY27. Dr. Sanjay Sharma, CEO (Q3 FY26 call)
• Park Medi World 2026-03: FY26 shows real improvement: OCF recovered to 329cr, the company turned net-cash-positive (+116) and debtor days fell 161->129 as collections improved, consistent with the 'debt-free by Feb-2026' guidance. But absolute debtors remain high at 129 days (structural government payer mix), and the FY25 OCF dip reflected the high-debtor WC build. screener_cash_flow + balance_sheet
• Park Medi World 2026-05: On results every quarter was a clean BEAT (FY26 rev +21%, PAT +27%), but the May-2026 call carried three documented guidance misses management did NOT acknowledge: FY26 bed goal missed (Panchkula slipped), ROCE delivered 18% vs '21% increasing', capex Rs 430cr vs ~Rs 280cr guided. The pattern: strong operating results, soft-pedalled forward-guidance misses. Treat its bed/capex/ROCE guidance with a haircut; trust the numbers. Dr. Ankit Gupta, MD (Q1 FY27 call)
• Nephrocare Health Services 2026-02: Directly resolves the Sep-2025 −9cr loss flag: it is a one-off, non-cash, pre-IPO capital-structure event (CCPS-to-equity conversion charge of Rs 37.2cr), NOT operating deterioration. Once excluded, underlying PAT is strongly positive and accelerating (adjusted PAT +71% YoY, margin 10->13%). The interest-spike that scared the data is the same item; post-IPO the borrowing base falls away. NephroPlus management (Q3 FY26 call)
• Nephrocare Health Services 2026-02: Explains the OPM volatility (latest 19% vs 23-24% guide): the swing is new-geography ramp cost, not core erosion, gross margin held ~77% throughout. Reported 24.3% adjusted EBITDA (excluding Saudi setup spend) shows the underlying per-session economics are intact and at guide. The explicit 100-150bps year-1 dilution from each new geography is the mechanical cause of the dips; it reverses as utilisation builds. NephroPlus management (Q3 FY26 call)
• Nephrocare Health Services 2026-03: Price, not the loss quarter, is the binding constraint. computed_fair_values + screener_ratios
• Dr Agarwals Health Care 2026-03: Asset-light day-care eye model: gross margin ~90% and steady ~27% EBITDA, but a ~20pp OPM-to-NPM gap is consumed by acquisition depreciation/amortization (dep 77cr = 14% of sales) + interest. The acquisition accounting, not operations, suppresses the bottom line, ROE only 6.8%. screener_margin_trends + quarterly
• SECTOR 28 April 2026: Credible voice frames the whole basket as entering a faster growth cycle: beds compounding ~13.1% (vs 5.6% prior 5y) + ARPOB +6-7% + stable occupancy => 18-20% sector revenue CAGR to FY29. The macro tailwind the per-stock revenue inflections sit inside, the topline acceleration is sector-wide, not stock-specific luck. Shankar Nath (summarizing IIFL report)
• SECTOR 28 April 2026: The runway is quantified: the listed set has 23,000+ beds in the pipeline to FY29 at 13.1% bed CAGR, capacity entering, not leaving. This explains the elevated investing-cash outflows (Apollo −3381 FY25, Medanta −1089 FY26) as a deliberate bed-addition wave rather than WC bleed, and it is the supply-side leg of the curve setup. Shankar Nath
• SECTOR 28 April 2026: (2) regulatory price caps on procedures/devices/tariffs can 'hurt margin overnight' (now demonstrated by the CGHS oncology clip on Max). Shankar Nath + Sahil Bhadviya (corroborated)
• Dr Agarwals Health Care 2026-06: Top line compounds steadily ~20%+ but for an acquisitive eye-care chain the DB cannot split same-store vs acquired growth, the heavy investing outflow (FY24 ICF −914cr) signals a large slice is bought, not organic. Treat the headline growth as part roll-up. screener · 10q (Dec-2023 to Mar-2026)
• Jupiter Life Line Hospitals 2026-06: Revenue tripled in 6 years on bed additions across Thane/Pune; recent quarters show the new-bed mix temporarily diluting sequential growth as fresh capacity ramps, classic mid-premium expansion, not demand loss. screener · both
• Kovai Medical Center & Hospital 2026-06: Steady single-cluster compounding: revenue 905->1586cr FY22->FY26 (~15% CAGR, +16% TTM), slower than the roll-ups but utterly consistent (no down years since FY21), the mark of a mature dominant-in-its-city asset. screener · both
• Indraprastha Medical Corporation 2026-06: MARGIN BRIDGE: the post-COVID margin doubled as the mature Apollo-managed asset re-filled and ARPOB rose, but the last two quarters show OPM rolling over (20→17) and opm_delta is now −1, the easy occupancy/pricing recovery is banked and margin may be at or just past its cyclical peak for a single fixed-bed asset. screener · both